CD34 and glioblastoma: Cluster of differentiation (CD)133 is a common marker of CSCs in multiple aggressive solid tumors, and Vora et al. constructed a CAR-T-targeting CD133 (CART133) and confirmed its superior efficacy in patient-derived glioblastoma (GBM) xenograft models, further indicating that CART133 in the treatment dose not induce toxicity in normal CD133+ hematopoietic stem cells and progenitor cells in humanized CD34+ mouse models [20].